Skip to main content

Day: April 6, 2020

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom. GIAPREZA is being made available for named patient emergency use based on a request from Professor Lui G. Forni, MBBS, Ph.D., at Royal Surrey County Hospital NHS Foundation Trust. According to English law, authorized medicines can be made available prior to commercial availability in order to fulfill special patient needs. GIAPREZA has been recently approved by the European...

Continue reading

Meritage Homes Releases Preliminary First Quarter 2020 Home Closings, Orders and Backlog

SCOTTSDALE, Ariz., April 06, 2020 (GLOBE NEWSWIRE) — Meritage Homes Corporation (NYSE: MTH), a leading U.S. homebuilder, today reported preliminary and unaudited home orders, closings and backlog for the first quarter of 2020.First quarter orders were up 23% year over year. Order cancellation rates were flat at 13% for the first quarter in both years, with an increase in March cancellations to 16% in 2020 over 12% in 2019 due to weakening business conditions in the latter half of March associated with the spread of the COVID-19 pandemic across the U.S. It is unclear how long these adverse conditions will persist or how they will impact future results.Home closings totaled 2,316 for the first quarter of 2020, up 31% compared to 1,765 for the first quarter of 2019.Ending backlog totaled 3,568 units as of March 31, 2020, a 12% increase...

Continue reading

EMISPHERE DEVELOPMENT UPDATE

ROSELAND, N.J., April 06, 2020 (GLOBE NEWSWIRE) — Novo Nordisk announced the European Commission (EC) has granted marketing authorization for Rybelsus®, (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycemic control as an adjunct to diet and exercise. The marketing authorization applies to all 27 European Union member states and the United Kingdom. Rybelsus® utilizes Emisphere Technologies, Inc.’s (“Emisphere” or the “Company”) (OTCBB:EMIS) proprietary Eligen® SNAC Carrier Technology.A copy of Novo Nordisk’s announcement can be found at https://www.novonordisk.com/media/news-details.2277630.htmlAbout EmisphereEmisphere is a drug delivery company that utilizes its proprietary Eligen® Technology to develop new oral formulations of therapeutic...

Continue reading

SII : SII_droits_de_vote_2020_03

Paris, le 06 avril 2020Déclaration mensuelle du nombre de droits de vote et du nombre d’actions composant le capital au 31 mars 2020Conformément aux articles L233-8 du Code de commerce et 223-16 du règlement général de l’AMFSII – Eric MATTEUCCI – Tél. : 01.42.84.82.22Ces informations sont disponibles sur le site de la sociétéhttp://www.groupe-sii.comPièce jointeSII_droits_de_vote_2020_03

Continue reading

Rockcliff Announces Commencement of Preliminary Economic Assessment and Provides Corporate Update

SUDBURY, Ontario, April 06, 2020 (GLOBE NEWSWIRE) — Rockcliff Metals Corporation (“Rockcliff” or the “Company”) (CSE: RCLF) (FRANKFURT: RO0, WKN: A2H60G) is pleased to provide an update on the Preliminary Economic Assessment (“PEA”) of the Tower and Rail properties and the Company’s COVID-19 response plan and operational update.Preliminary Economic AssessmentRockcliff will be commencing immediately the preparation of the PEA incorporating the following key elements:Sequential development of the 100% owned Tower and Rail projects to provide feed to the leased Bucko Mill;Application of the mine approach, methodology and productivities to the resources established in the updated Technical Resource Estimates reports. A separate mine methodology press release is planned within a month;Apply results from the recently completed metallurgical...

Continue reading

TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that the U.S. Food and Drug Administration (FDA) has granted TRACON a Type B Teleconference to take place on May 8, 2020 to discuss the trial design for a potential pivotal study of envafolimab in sarcoma (ENVASARC).Expected Envafolimab Milestones Over the Next 6 MonthsType B teleconference meeting with the FDA on May 8 to discuss the potential pivotal trial design of ENVASARC for envafolimab in sarcomaApply for orphan drug designation for envafolimab in soft tissue...

Continue reading

Agillic suspends financial guidance for 2020 due to pandemic coronavirus

Announcement no. 9 2020Copenhagen – 6 April 2020 – Agillic A/S (Nasdaq First North Copenhagen: AGILC) informs that due to pandemic coronavirus, financial guidance for 2020 is suspended. A new outlook will be presented as soon as possible.As a result of the COVID-19 and the government initiatives to contain the virus, markets and businesses are affected in a varying degree. The impact on SaaS-businesses, such as Agillic, is not showing immediately as client subscriptions are recurring and running for a year or more.However, it is difficult to predict how long the pandemic will persist, which measures the government will take to mitigate the situation and how it affects the business of Agillic’s clients. Due to the unpredictable situation, forecasts regarding business performance have become uncertain, and the Company, therefore, suspends...

Continue reading

Jacada To Offer Easy-to-Launch Customer Service Automation Solutions for Contact Centers Affected by the Coronavirus Pandemic 

ATLANTA, April 06, 2020 (GLOBE NEWSWIRE) — Jacada, Inc., a global pioneer in customer service automation software, has been monitoring the impact the coronavirus has had on contact centers. In response, Jacada is offering award-winning customer service automation solutions at no cost during the COVID-19 pandemic. The offer is available for a limited time. Conditions apply.“Today, customer operations leaders across industries are responding to changing customer interaction patterns. The unexpected increase in demand for customer service has hit contact centers at a time when the customer service workforce is at a reduced capacity due to work-at-home constraints and the unfortunate case of agents falling ill due to the coronavirus”.“As customers expect businesses to serve them with empathy and clarity, the need for agility within...

Continue reading

California Bank of Commerce Launches Sponsor Finance Division

OAKLAND, Calif., April 06, 2020 (GLOBE NEWSWIRE) — California Bank of Commerce (CBC) announces the launch of its Sponsor Finance Lending Division, led by well-known dealmaker Larry LaCroix.The division works closely with private equity firms (including Search Funds) and direct lenders to provide cash flow-based senior debt financing.“We’re pleased to not only announce this new division but, also excited to have Larry join our team,” said Steve Shelton, President and Chief Executive Officer of California Bank of Commerce. “His leadership and background in Sponsor Finance position the bank for continued success.”In moving into the area of Sponsor Funding on a national level, CBC selected LaCroix and named him an Executive Vice President as well as manager of the new program. LaCroix is a veteran leader in the finance industry, having...

Continue reading

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaksPromising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five monthsGSK to make equity investment of $250 million in VirLONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) — LSE announcement — GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.